|Title:||Potassium salt of S-omeprazole|
|Abstract:||The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-ben zimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.|
|Inventor(s):||Kronstrom; Anders (Stockholm, SE), Leander; Eva (Skiptvet, NO), Mattson; Anders (Taby, SE)|
|Assignee:||AstraZeneca AB (Sodertalje, SE)|
|Filing Date:||Feb 14, 2002|
|Claims:||1. The potassium salt of S-omeprazole, wherein the compound is characterized by the following peaks in its X-ray powder diffractogram: |
2. A process for the preparation of the potassium salt of S-omeprazole of claim 1, which process comprises the following steps: a) oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimi dazole into S-omeprazole in an organic solvent; b) converting the S-omeprazole into the corresponding potassium salt of S-omeprazole by treating the S-omeprazole with a potassium source; and c) isolating the potassium salt of S-omeprazole thus obtained.
3. The process according to claim 2, wherein the organic solvent used in step a) is toluene.
4. The process according to claim 2 or 3, wherein the potassium source used in step b) is methanolic potassium methoxide or methanolic potassium hydroxide.